Dr. Mihir Raval, MD
Claim this profileNew York Oncology Hematology, P.C.
Studies Lymphoma
Studies Plasma Cell Neoplasms
4 reported clinical trials
12 drugs studied
Area of expertise
1Lymphoma
Stage I
Stage IV
Stage III
2Plasma Cell Neoplasms
Affiliated Hospitals
Clinical Trials Mihir Raval, MD is currently running
Tazemetostat + Lenalidomide + Rituximab
for Follicular Lymphoma
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.
Recruiting1 award Phase 34 criteria
Selinexor + DRd
for Multiple Myeloma
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.
Recruiting1 award Phase 29 criteria
More about Mihir Raval, MD
Clinical Trial Related5 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Mihir Raval, MD has experience with
- Lenalidomide
- Tazemetostat
- Rituximab
- Belantamab Mafodotin
- Pomalidomide Plus Low Dose Dexamethasone
- Brentuximab Vedotin
Breakdown of trials Mihir Raval, MD has run
Lymphoma
Plasma Cell Neoplasms
Follicular Lymphoma
Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mihir Raval, MD specialize in?
Mihir Raval, MD focuses on Lymphoma and Plasma Cell Neoplasms. In particular, much of their work with Lymphoma has involved Stage I patients, or patients who are Stage IV.
Is Mihir Raval, MD currently recruiting for clinical trials?
Yes, Mihir Raval, MD is currently recruiting for 2 clinical trials in Albany New York. If you're interested in participating, you should apply.
Are there any treatments that Mihir Raval, MD has studied deeply?
Yes, Mihir Raval, MD has studied treatments such as Lenalidomide, Tazemetostat, Rituximab.
What is the best way to schedule an appointment with Mihir Raval, MD?
Apply for one of the trials that Mihir Raval, MD is conducting.
What is the office address of Mihir Raval, MD?
The office of Mihir Raval, MD is located at: New York Oncology Hematology, P.C., Albany, New York 12206 United States. This is the address for their practice at the New York Oncology Hematology, P.C..
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.